Diagnostic and Management Problems of a Patient with Severe Life-Threatening Acute Hypocalcemia: A Case Report

Arvin Wiranata Lianto1, Birgita Maria Ratu Rosari Bas1, Robert Dwitama Adiwinoto2, Libriansyah2

1Dr. Ramelan Naval Hospital, Surabaya, Indonesia
2Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Dr. Ramelan Naval Hospital, Surabaya, Indonesia

ARTICLE INFO

Article history:
Received 5 February 2022
Received in revised form 14 March 2022
Accepted 15 April 2022
Available online 28 April 2022

Keywords:
Hypocalcemia, Tetany, Vitamin D deficiency, Phenytoin

*) Corresponding author:
arvinwiranatalianto@gmail.com

ABSTRACT

Hypocalcemia is a common electrolyte disorder. Acute hypocalcemia is a life-threatening condition that needs prompt evaluation and management. We present a case of a 54-year-old woman presented to emergency room with muscle spasm and involuntary movement. Upon physical examination, the patient was disoriented and the Trousseau’s sign was bilaterally positive when the cuff was inflated. Blood test revealed severe hypocalcemia with albumin-corrected serum total calcium levels 1.77 mg/dL. Following extensive diagnostic workups, there were no alternative explanations other than vitamin D deficiency. Despite aggressive intravenous (IV) calcium correction and high-dose vitamin D supplementation the calcium levels gradually decreased and neurological symptoms relapsed. The use of phenytoin to treat neurological symptoms decreased calcium levels further. The patient was eventually discharged with oral calcium and calcitriol supplementation with minimal symptoms. This case highlights the importance of thorough diagnostic workups and judicious use of anticonvulsant drugs in hypocalcemia for optimal treatment outcome.

Introduction

Hypocalcemia is a common electrolyte disorder, but the diagnosis requires a high clinical suspicion index by the clinician. The clinical manifestations of hypocalcemia are variable, as the low serum calcium levels may impair any organ function. Acute, new onset hypocalcemia may represent a life-threatening situation requiring immediate intervention, while chronic reduction in serum calcium levels is sometimes asymptomatic or slightly symptomatic.1 It is usually defined as corrected serum total calcium levels < 8.5 mg/dL, taking serum albumin levels into account. Disorders causing hypocalcemia can be divided into parathyroid hormone (PTH) and non-PTH mediated. Several organs (kidneys, liver, skeleton, gut) and vitamin D metabolism play a major role in non-PTH mediated cases.2,3

In all cases, the evaluation of the causes by diagnostic workup and management of hypocalcemia are essential and need to be addressed simultaneously. The goal of treatment is to replenish serum calcium to the normal range, to resolve or minimize symptoms.4 When the etiology of hypocalcemia is known, management of the underlying disorder is important for optimal therapy. Vitamin D deficiency should be corrected with vitamin D supplementation. In practice, vitamin D deficiency is defined as serum 25-hydroxyvitamin D (25(OH) D) concentrations <10 ng/mL, while vitamin D insufficiency is defined as serum 25(OH)D concentrations 11 – 20 ng/mL.5 Currently, 25(OH)D levels below 20 ng/mL, with resultant consistent elevation of PTH are considered indicative of vitamin D deficiency.6 Vitamin D deficiency or insufficiency may result from inadequate sunlight exposure, malabsorption, and certain medications that impair vitamin D metabolism.2,7,8

Here we report the case of a patient with new-onset severe acute hypocalcemia associated with vitamin D deficiency who developed treatment-resistant hypocalcemia during the course of hospitalization. We also described our diagnostic approach and clinical management.

Case Report

A 52-year-old female with no medical history was admitted to the emergency department after a road traffic accident. She was the driver of a motorcycle involved in an intersection collision with another motorcycle. Physical examination showed the patient was alert with Glasgow coma score (GCS) score 15, pulse 100 beats per minute, respiratory rate

Biomolecular and Health Science Journal
Available at https://e-journal.unair.ac.id/bhsj; DOI: 10.20473/bhsj.v5.i1.34295

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
22 times per minute, axillary temperature 36.5°C, weighed approximately 65 kgs. With a visual analogue scale (VAS) of 6, she experienced significant discomfort across her left flank. The initial management was in line with the Advanced Trauma Life Support (ATLS) protocol.

Gross hematuria was detected when the urethral catheter was placed. Furthermore, no further injuries were discovered during the tertiary survey. Microscopic hematuria was discovered with moderately increased. The following days, the patient underwent several diagnostic workups to investigate the etiology of hypocalcemia. Serum intact PTH levels was ordered and revealed high-normal levels (57.8 pg/mL). Serum magnesium (Mg) was within normal limit (2.2 mg/dL). Thyroid function test was also within normal limit. A contrast-enhanced computed tomography (CT) scan of abdomen was obtained to exclude acute abdominal events. Skeletal survey did not reveal any lesions. Neck ultrasonography was performed with normal results. 24 hours urinary calcium excretion was normal. Serum 25(OH)D levels was decreased (13.9 ng/mL), indicating vitamin D insufficiency status. The diagnostic findings and normal range were described in table 1.

Over the following days, total serum calcium levels gradually decreased, despite aggressive IV calcium correction and high-dose vitamin D supplementation (10,000 IU oral calcitriol daily). Meanwhile, the neurologic symptoms relapsed as the patient complained about bothersome twitching in the lower legs. In light of these findings, phenytoin regimen was initiated (100 mg IV phenytoin diluted in normal saline, 3 times daily) upon consultation with neurology. However, calcium and 25(OH)D levels did not substantially increase to normal range levels, therefore phenytoin was stopped. The progression of mineral metabolism parameter was presented in table 2. The patient was eventually discharged after 3 weeks of admission with a prescription for oral calcium lactate 1.500 mg daily in divided dose and oral calcitriol 10.000 IU daily with improvement neurologic symptoms.

![Figure 1. Electrocardiogram showed markedly prolonged QT interval at admission (A) and improvement after calcium replenishment (B)](image)

**Table 1. Laboratory results and normal range for tested parameters**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Result</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium</td>
<td>0.90 mg/dL</td>
<td>8.60-10.30 mg/dL</td>
</tr>
<tr>
<td>Albumin</td>
<td>2.91 g/dL</td>
<td>3.40-5.40 g/dL</td>
</tr>
<tr>
<td>Phosphate</td>
<td>3.10 mg/dL</td>
<td>3.00-4.50 mg/dL</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>0.80 mg/dL</td>
<td>0.60-1.30 mg/dL</td>
</tr>
<tr>
<td>AST</td>
<td>42 U/L</td>
<td>0-35 U/L</td>
</tr>
<tr>
<td>ALT</td>
<td>25 U/L</td>
<td>0-37 U/L</td>
</tr>
<tr>
<td>Intact PTH</td>
<td>57.80 pg/mL</td>
<td>15-65 pg/mL</td>
</tr>
<tr>
<td>Magnesium</td>
<td>2.20 mg/dL</td>
<td>1.90-2.50 mg/dL</td>
</tr>
<tr>
<td>TSHs</td>
<td>5.35 μIU/mL</td>
<td>0.35-5.10 μIU/mL</td>
</tr>
<tr>
<td>T4</td>
<td>7.04 ng/mL</td>
<td>5.13-14.06 ng/mL</td>
</tr>
<tr>
<td>T3</td>
<td>0.63 μg/dL</td>
<td>0.84-2.02 μg/dL</td>
</tr>
<tr>
<td>24-h urinary calcium</td>
<td>101.30 mg</td>
<td>100-250 mg</td>
</tr>
<tr>
<td>25(OH)D</td>
<td>13.90 ng/mL</td>
<td>30-80 ng/mL</td>
</tr>
</tbody>
</table>
At admission the severe drop in serum calcium levels. Normal range (57.8 pg/mL) this might be a response to serum magnesium, and phosphate levels were normal. First order of investigation in evaluating hypocalcemia investigation proceeded to laboratory workups. Acute hypocalcemia in our patient. Scan also excluded acute pancreatitis as the cause of pharmacological history to exclude any drug beginning evaluation of medical, familial, and personal history. Pepe et al., investigation of hypocalcemia should prompt the evaluation of calcium levels. The final step in investigating hypocalcemia is to measure serum 25(OH)D levels. Our patient serum 25(OH)D levels was 13.9 ng/mL, indicating vitamin D insufficiency. However, serum 25(OH)D levels below 20 ng/mL, with resultant consistent elevation of PTH as seen in this present case might be considered as vitamin D deficiency. The possibility of vitamin D deficiency in this patient was also supported by the lower normal levels (101.3 mg) of 24-hour urine calcium excretion finding. Vitamin D deficiency may result from inadequate sunlight exposure, malabsorption, and certain medications that impair vitamin D metabolism. Normal skeletal survey from bone radiograph excluded skeletal disorders (osteomalacia). While we had not fully investigated the probability of vitamin D malabsorption in this present case we strongly suspected malabsorption as the underlying disorder of vitamin D deficiency. Nevertheless, treatment should be initiated irrespective of the cause, according to the algorithm (figure 2) in the management of the adult with vitamin D deficiency.

Calcium supplementation with the goal to replenish serum calcium to the normal range is important in the acute setting. Intravenous calcium solutions are hyperosmolar and should be administered through a large central vein, whenever possible. One gram of calcium gluconate contains 93 mg of elemental calcium, therefore 100-300 mg of elemental calcium (1–3 g calcium gluconate) in 100 mL dextrose over 10 min infusion followed by continuous infusion of 0.5–1.5 mg of elemental calcium/kg per hour is a rational approach. Due to the presence of vitamin D deficiency, a supplementation with oral calcitriol 2000 IU daily is recommended for serum 25(OH)D levels 12-20 ng/mL along with calcium replenishment. We give our patient a larger dose supplementation with oral calcitriol 10.000 IU daily in divided dose because of the possibility of malabsorption. Some medications such as phenytoin, phenobarbital, and rifampicin can induce hepatic p450 enzymes and accelerate metabolism of vitamin D. Considering some of the aforementioned drugs might be used in practice to treat the neurological manifestations of hypocalcemia, judicious use of anticonvulsants is essential in managing hypocalcemic patient. The calcium levels in this patient decreased when phenytoin regimen (IV loading and oral dose) was given to treat the neurological symptoms might be due to increased catabolism of vitamin D. Therapy with standard anticonvulsants is ineffective and may even exacerbate these seizures (by an anti-vitamin D effect). Because of that, the best treatment for patient with acute severe hypocalcemia is intravenous calcium solutions and continued with oral calcitriol until the symptoms have cleared.

**Table 2. Mineral metabolism parameters upon admission and after treatment**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>At admission</th>
<th>24-hour of treatment</th>
<th>1st week of treatment</th>
<th>2nd week of treatment</th>
<th>3rd week – discharged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium (mg/dL)</td>
<td>0.90</td>
<td>8.90</td>
<td>6.60-8.40</td>
<td>8.10</td>
<td>8.70-7.90</td>
</tr>
<tr>
<td>25(OH)D (ng/mL)</td>
<td>-</td>
<td>-</td>
<td>13.90</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Intact PTH (pg/mL)</td>
<td>-</td>
<td>-</td>
<td>57.80</td>
<td>21.80</td>
<td>-</td>
</tr>
</tbody>
</table>
Conclusion

Hypocalcemia might present with various clinical manifestations. The presence of tetany should raise the awareness of a physician for prompt calcium levels evaluation. Whenever available, serum 25(OH)D levels should be obtained in the case of acute hypocalcemia. Antiepileptic drugs should be used with caution in treating the neurological symptoms of hypocalcemia associated with vitamin D deficiency, as it may increase catabolism of vitamin D. Therapy with standard anticonvulsants is ineffective and may even exacerbate these seizures (by an anti–vitamin D effect). Because of that, the best treatment for patient with acute severe hypocalcemia is intravenous calcium solutions and continued with oral calcitriol until the symptoms have cleared.

Acknowledgment

We would like to thank the patient for her consent to this case report publication.

Conflict of Interest

The author stated there is no conflict of interest.

References